What is it about?

In clinical practice, treatment timing of multi-targeted kinase inhibitors for the patients with radioiodine refractory differentiated thyroid cancer (RAIR-DTC) is one of the important clinical questions. In this post-hoc analysis of a phase III trial (SELECT), we explore whether baseline tumor burden may predict treatment outcomes and help considering introduction of lenvatinib for RAIR-DTC patients

Featured Image

Why is it important?

Higher baseline tumor burden predicted worse survival outcomes. although lenvatinib showed high response rate irrespective of tumor size. The cut-off level of 40 mm in sum of the diameters may help considering optimal timing of lenvatinib for RAIR-DTC patients.

Perspectives

In the era of cancer genomic medicine, there is still role of multi-targeted kinase inhibitors for RAIR-DTC. Hence, it is important to use all of the available treatment options for these patients.

Naomi Kiyota
Kobe University Hospital

Read the Original

This page is a summary of: Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial, Cancer, April 2022, Wiley, DOI: 10.1002/cncr.34181.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page